A US-based KOL discusses the prostate cancer treatment algorithm from localized through to metastatic castration-resistant disease, covering the impact of PSMA-PET imaging on staging, risk stratification and molecular profiling. Reimbursement and prior authorization dynamics were explored, alongside pipeline agents including selective PARP1 inhibitors and alpha-emitting radioligand therapies.

This interview was conducted on March 12, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.